Research and Markets - Global Antibody Drug Conjugates (ADC) Market 2017-2022: Kadcyla but will be Surpassed by Adcetris by 2022 as the Market Leader

DUBLIN, April 06, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Antibody Drug Conjugates (ADC) Market - Analysis By Drugs (Adcetris, Kadcyla), Pipeline Drugs, Regulations: Opportunities and Forecasts (2017-2022)" report to their offering.

Global market is projected to display a robust growth represented by a CAGR of 21.82% during 2017-2022, chiefly driven by large number of ADC drugs in pipeline, rising number of cancer patients and wider therapeutic window offered by antibody drug conjugates.

Over the recent years, the global antibody drug conjugates industry has been growing rapidly as the global sales of Adcetris and Kadcyla have been witnessing rapid growth after their approval. Globally, the growth in the antibody drug conjugates market is driven by large number of ADC drugs in pipeline, rise in global incidences of cancer and wider therapeutic window offered by ADCs.

Among the drugs, Kadcyla currently dominates the antibody drug conjugates market but will be surpassed by Adcetris in forecasted period. Among the regions, North America is predicted to advance at the highest rate, mainly driven by increase in several ADC molecules expected to gain FDA approval in next few years

The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global food service equipment market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)

- Antibody Drug Conjugates Market (ADC) Market
- Adcetris Market
- Kadcyla Market
- ADC Pipeline - By Developer, Phase, Indication and Status
- ADC Pipeline - By Cytotoxic Payload, Linker and Target

- Antibody Drug Conjugates Market (ADC) Market
- Adcetris Market
- Kadcyla Market
- ADC Pipeline - By Developer, Phase, Indication and Status
- ADC Pipeline - By Cytotoxic Payload, Linker and Target

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Strategic Recommendation
3.1 Focus on marketing ADCs at lower cost in Asia Pacific region
3.2 Multiple Licensing and Collaboration
3.3 Outsourcing of ADC manufacturing to CMOs

4. Antibody Drug Conjugates Product Overview

5. Global Antibody Drug Conjugates Market: Growth and Forecast

6. Global Antibody Drug Conjugates Market: By Drug (Adcetris, Kadcyla)

7. Global Antibody Drug Conjugates Market: Pipeline Analysis

8. Global Antibody Drug Conjugates Market: Regional Analysis

9. Market Dynamics

10. Market Trends

11. Porter's Five Forces Analysis - Antibody Drug Conjugates Market

12. SWOT Analysis - Antibody Drug Conjugates Market

13. Policy and Regulatory Landscape

14. Company Profiles

- AbbVie Inc
- Cellldex Therapeutics
- F. Hoffmann-La Roche Ltd
- ImmunoGen Inc
- Pfizer Inc.
- Progenics Pharmaceuticals
- Sanofi
- Seattle Genetics
- Synthon
- Takeda

For more information about this report visit http://www.researchandmarkets.com/research/qqg5nw/global_antibody

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com